Symbols / TARA $5.45 +0.55%
TARA Chart
About
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 294.76M |
| Enterprise Value | 142.56M | Income | -57.44M | Sales | — |
| Book/sh | 3.67 | Cash/sh | 2.88 | Dividend Yield | — |
| Payout | 0.00% | Employees | 46 | IPO | — |
| P/E | — | Forward P/E | -3.78 | PEG | — |
| P/S | — | P/B | 1.49 | P/C | — |
| EV/EBITDA | -2.22 | EV/Sales | — | Quick Ratio | 14.34 |
| Current Ratio | 14.58 | Debt/Eq | 1.71 | LT Debt/Eq | — |
| EPS (ttm) | -1.34 | EPS next Y | -1.44 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -20.64% |
| ROE | -31.60% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 54.08M |
| Shs Float | 47.46M | Short Float | 9.30% | Short Ratio | 4.04 |
| Short Interest | — | 52W High | 7.82 | 52W Low | 2.77 |
| Beta | 1.44 | Avg Volume | 1.07M | Volume | 519.59K |
| Target Price | $25.71 | Recom | Strong_buy | Prev Close | $5.42 |
| Price | $5.45 | Change | 0.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.71
Mean price target
2. Current target
$5.45
Latest analyst target
3. DCF / Fair value
$-12.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.45
Low
$23.00
High
$30.00
Mean
$25.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-04 | init | JP Morgan | — → Overweight | $27 |
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2026-01-07 | init | Piper Sandler | — → Overweight | $24 |
| 2025-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-11-19 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-05-22 | init | Jones Trading | — → Buy | $21 |
| 2025-04-28 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2025-04-16 | init | Scotiabank | — → Sector Outperform | $12 |
| 2025-03-14 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-11 | init | LifeSci Capital | — → Outperform | $22 |
| 2025-03-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-12-06 | reit | Guggenheim | Buy → Buy | $20 |
| 2024-12-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-08-12 | main | Oppenheimer | Outperform → Outperform | $25 |
| 2024-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-04-22 | main | Oppenheimer | Outperform → Outperform | $30 |
| 2024-04-08 | main | HC Wainwright & Co. | Buy → Buy | $23 |
| 2024-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $23 |
- JP Morgan Initiates Coverage on TARA with Overweight Rating and $27 PT | TARA Stock News - GuruFocus Wed, 04 Mar 2026 13
- Bladder cancer trial shares new results from 25 patients at ASCO - Stock Titan hu, 22 Jan 2026 08
- Equities Analysts Offer Predictions for TARA Q1 Earnings - MarketBeat Fri, 13 Mar 2026 10
- Protara Therapeutics Announces $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative hu, 04 Dec 2025 08
- Insiders Buying Protara Therapeutics Might Wish They Invested More, Stock Gains 30% - Yahoo Finance Mon, 24 Nov 2025 08
- Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns - simplywall.st hu, 15 Jan 2026 08
- SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits ue, 24 Feb 2026 07
- Protara Prices $75 Mln Offering To Advance TARA-002 And Broader Pipeline - Nasdaq Fri, 05 Dec 2025 08
- Bladder cancer drug hits 68% response; Protara sees cash runway into 2028 - Stock Titan ue, 10 Mar 2026 12
- FY2030 Earnings Forecast for TARA Issued By HC Wainwright - MarketBeat hu, 12 Mar 2026 11
- $TARA stock is up 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Sep 2025 07
- Protara Announces Pricing of $75 Million Public Offering - Yahoo Finance hu, 04 Dec 2025 08
- Protara Therapeutics (Nasdaq: TARA) starts $75M stock and pre-funded warrant sale - Stock Titan hu, 04 Dec 2025 08
- Protara Therapeutics (Nasdaq: TARA) prices 13,043,479-share, $75M public deal - Stock Titan hu, 04 Dec 2025 08
- Trial tests first IV choline therapy for patients on long-term IV nutrition - Stock Titan Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 28000 | — | — | Stock Award(Grant) at price 0.00 per share. | FABBIO PATRICK | Chief Financial Officer | — | 2026-01-16 00:00:00 | D |
| 1 | 87000 | — | — | Stock Award(Grant) at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2026-01-16 00:00:00 | D |
| 2 | 30000 | — | — | Stock Award(Grant) at price 0.00 per share. | ZUMMO JACQUELINE | Chief Operating Officer | — | 2026-01-16 00:00:00 | D |
| 3 | 26000 | — | — | Stock Award(Grant) at price 0.00 per share. | CONKLING WILLIAM | Officer | — | 2026-01-16 00:00:00 | D |
| 4 | 9500 | — | — | Stock Award(Grant) at price 0.00 per share. | FRY HANNAH | Officer | — | 2026-01-16 00:00:00 | D |
| 5 | 26000 | — | — | Stock Award(Grant) at price 0.00 per share. | NICACIO LEONARDO VIANA M.D. | Officer | — | 2026-01-16 00:00:00 | D |
| 6 | 18667 | — | — | Stock Gift at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2025-06-27 00:00:00 | D |
| 7 | 300000 | — | — | Stock Gift at price 0.00 per share. | SHEFFERMAN JESSE M | Chief Executive Officer | — | 2025-06-24 00:00:00 | D |
| 8 | 50000 | — | — | Stock Award(Grant) at price 0.00 per share. | CONKLING WILLIAM | Officer | — | 2025-06-02 00:00:00 | D |
| 9 | 20000 | 63800 | — | Purchase at price 3.19 per share. | LEVY RICHARD S | Director | — | 2025-05-14 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -64.24M | -48.86M | -43.28M | -35.07M |
| TotalUnusualItems | 49.00K | 36.00K | 12.00K | -29.50M |
| TotalUnusualItemsExcludingGoodwill | 49.00K | 36.00K | 12.00K | -29.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -57.44M | -44.60M | -40.42M | -65.95M |
| ReconciledDepreciation | 362.00K | 332.00K | 341.00K | 248.00K |
| EBITDA | -64.19M | -48.82M | -43.27M | -64.57M |
| EBIT | -64.55M | -49.15M | -43.61M | -64.81M |
| NetInterestIncome | 6.33M | 4.13M | 3.18M | 1.09M |
| InterestExpense | 1.14M | 1.74M | ||
| InterestIncome | 6.33M | 4.13M | 3.18M | 2.23M |
| NormalizedIncome | -57.49M | -44.63M | -40.43M | -36.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -57.44M | -44.60M | -40.42M | -65.95M |
| TotalExpenses | 64.55M | 49.15M | 43.61M | 37.55M |
| TotalOperatingIncomeAsReported | -64.55M | -49.15M | -43.61M | -67.06M |
| DilutedAverageShares | 20.59M | 11.33M | 11.26M | 11.23M |
| BasicAverageShares | 20.59M | 11.33M | 11.26M | 11.23M |
| DilutedEPS | -2.17 | -3.57 | -5.86 | -4.21 |
| BasicEPS | -2.17 | -3.57 | -5.86 | -4.21 |
| DilutedNIAvailtoComStockholders | -57.44M | -44.60M | -40.42M | -65.95M |
| NetIncomeCommonStockholders | -57.44M | -44.60M | -40.42M | -65.95M |
| NetIncome | -57.44M | -44.60M | -40.42M | -65.95M |
| NetIncomeIncludingNoncontrollingInterests | -57.44M | -44.60M | -40.42M | -65.95M |
| NetIncomeContinuousOperations | -57.44M | -44.60M | -40.42M | -65.95M |
| PretaxIncome | -57.44M | -44.60M | -40.42M | -65.95M |
| OtherIncomeExpense | 779.00K | 423.00K | 12.00K | -29.50M |
| OtherNonOperatingIncomeExpenses | 730.00K | 387.00K | ||
| SpecialIncomeCharges | 0.00 | -29.52M | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | 29.52M | 0.00 | |
| GainOnSaleOfSecurity | 49.00K | 36.00K | 12.00K | 17.00K |
| NetNonOperatingInterestIncomeExpense | 6.33M | 4.13M | 3.18M | 1.09M |
| InterestExpenseNonOperating | 1.14M | 1.74M | ||
| InterestIncomeNonOperating | 6.33M | 4.13M | 3.18M | 2.23M |
| OperatingIncome | -64.55M | -49.15M | -43.61M | -37.55M |
| OperatingExpense | 64.55M | 49.15M | 43.61M | 37.55M |
| ResearchAndDevelopment | 42.63M | 31.70M | 24.99M | 16.81M |
| SellingGeneralAndAdministration | 21.92M | 17.45M | 18.62M | 20.74M |
| GeneralAndAdministrativeExpense | 21.92M | 17.45M | 18.62M | 20.74M |
| OtherGandA | 21.92M | 17.45M | 18.62M | 20.74M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 53.59M | 35.04M | 11.36M | 11.27M |
| ShareIssued | 53.59M | 35.04M | 11.36M | 11.27M |
| TotalDebt | 3.36M | 4.48M | 5.47M | 6.38M |
| TangibleBookValue | 193.48M | 163.89M | 65.66M | 102.00M |
| InvestedCapital | 196.41M | 167.13M | 68.32M | 102.08M |
| WorkingCapital | 148.56M | 161.19M | 62.56M | 80.41M |
| NetTangibleAssets | 193.48M | 163.89M | 65.66M | 102.00M |
| CapitalLeaseObligations | 3.36M | 4.48M | 5.47M | 6.38M |
| CommonStockEquity | 196.41M | 167.13M | 68.32M | 102.08M |
| TotalCapitalization | 196.41M | 167.13M | 68.32M | 102.08M |
| TotalEquityGrossMinorityInterest | 196.41M | 167.13M | 68.32M | 102.08M |
| StockholdersEquity | 196.41M | 167.13M | 68.32M | 102.08M |
| GainsLossesNotAffectingRetainedEarnings | 90.00K | 2.00K | -31.00K | -688.00K |
| OtherEquityAdjustments | 90.00K | 2.00K | -31.00K | -688.00K |
| RetainedEarnings | -302.42M | -244.98M | -200.38M | -159.96M |
| AdditionalPaidInCapital | 498.69M | 412.08M | 268.73M | 262.72M |
| CapitalStock | 54.00K | 35.00K | 11.00K | 11.00K |
| CommonStock | 54.00K | 35.00K | 11.00K | 11.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 13.06M | 14.32M | 10.63M | 11.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.12M | 3.36M | 4.48M | 5.47M |
| LongTermDebtAndCapitalLeaseObligation | 2.12M | 3.36M | 4.48M | 5.47M |
| LongTermCapitalLeaseObligation | 2.12M | 3.36M | 4.48M | 5.47M |
| CurrentLiabilities | 10.94M | 10.96M | 6.15M | 5.74M |
| CurrentDebtAndCapitalLeaseObligation | 1.24M | 1.12M | 983.00K | 917.00K |
| CurrentCapitalLeaseObligation | 1.24M | 1.12M | 983.00K | 917.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.27M | 2.53M | 2.11M | 2.54M |
| PayablesAndAccruedExpenses | 6.43M | 7.30M | 3.05M | 2.28M |
| CurrentAccruedExpenses | 2.96M | 2.88M | 620.00K | 694.00K |
| Payables | 3.47M | 4.43M | 2.43M | 1.59M |
| TotalTaxPayable | 41.00K | |||
| AccountsPayable | 3.47M | 4.43M | 2.43M | 1.59M |
| TotalAssets | 209.47M | 181.45M | 78.95M | 113.29M |
| TotalNonCurrentAssets | 49.96M | 9.30M | 10.25M | 27.14M |
| OtherNonCurrentAssets | 765.00K | 772.00K | 756.00K | 761.00K |
| NonCurrentPrepaidAssets | 0.00 | 272.00K | 544.00K | |
| InvestmentsAndAdvances | 42.34M | 0.00 | 0.00 | 17.89M |
| InvestmentinFinancialAssets | 42.34M | 0.00 | 0.00 | 17.89M |
| AvailableForSaleSecurities | 42.34M | 17.89M | 39.47M | |
| GoodwillAndOtherIntangibleAssets | 2.93M | 3.25M | 2.66M | 84.00K |
| OtherIntangibleAssets | 2.93M | 3.25M | 2.66M | 84.00K |
| Goodwill | 0.00 | 29.52M | ||
| NetPPE | 3.93M | 5.28M | 6.56M | 7.87M |
| AccumulatedDepreciation | -1.47M | -1.11M | -824.00K | -483.00K |
| GrossPPE | 5.40M | 6.39M | 7.38M | 8.35M |
| Leases | 553.00K | 553.00K | 553.00K | 553.00K |
| OtherProperties | 4.15M | 5.25M | 6.23M | 7.24M |
| MachineryFurnitureEquipment | 695.00K | 587.00K | 599.00K | 557.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 159.50M | 172.16M | 68.70M | 86.15M |
| OtherCurrentAssets | 65.00K | 2.00K | 37.00K | 127.00K |
| RestrictedCash | 0.00 | |||
| PrepaidAssets | 2.63M | 1.86M | 2.85M | 1.16M |
| Receivables | 1.26M | 0.00 | 242.00K | 486.00K |
| AccruedInterestReceivable | 1.26M | 0.00 | 242.00K | 486.00K |
| CashCashEquivalentsAndShortTermInvestments | 155.55M | 170.29M | 65.58M | 84.37M |
| OtherShortTermInvestments | 105.90M | 7.49M | 25.99M | 60.24M |
| CashAndCashEquivalents | 49.66M | 162.80M | 39.59M | 24.13M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -56.46M | -35.87M | -37.60M | -26.58M |
| RepurchaseOfCapitalStock | -91.00K | -90.00K | -228.00K | |
| RepaymentOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 80.96M | 136.01M | 0.00 | 0.00 |
| CapitalExpenditure | -94.00K | -63.00K | -45.00K | -120.00K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 50.40M | 163.54M | 40.33M | 24.87M |
| BeginningCashPosition | 163.54M | 40.33M | 24.87M | 36.47M |
| ChangesInCash | -113.14M | 123.21M | 15.46M | -11.60M |
| FinancingCashFlow | 82.72M | 139.87M | -91.00K | -90.00K |
| CashFlowFromContinuingFinancingActivities | 82.72M | 139.87M | -91.00K | -90.00K |
| NetOtherFinancingCharges | -799.00K | -83.00K | -91.00K | |
| ProceedsFromStockOptionExercised | 2.55M | 3.94M | 0.00 | 0.00 |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 80.96M | 136.01M | 0.00 | -90.00K |
| CommonStockPayments | -91.00K | -90.00K | -228.00K | |
| CommonStockIssuance | 80.96M | 136.01M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| InvestingCashFlow | -139.49M | 19.16M | 53.11M | 14.95M |
| CashFlowFromContinuingInvestingActivities | -139.49M | 19.16M | 53.11M | 14.95M |
| NetInvestmentPurchaseAndSale | -139.40M | 19.22M | 53.15M | 15.07M |
| SaleOfInvestment | 65.23M | 48.60M | 65.34M | 58.62M |
| PurchaseOfInvestment | -204.63M | -29.38M | -12.19M | -43.55M |
| NetPPEPurchaseAndSale | -94.00K | -63.00K | -45.00K | -120.00K |
| PurchaseOfPPE | -94.00K | -63.00K | -45.00K | -120.00K |
| OperatingCashFlow | -56.37M | -35.81M | -37.56M | -26.46M |
| CashFlowFromContinuingOperatingActivities | -56.37M | -35.81M | -37.56M | -26.46M |
| ChangeInWorkingCapital | -2.94M | 4.01M | -4.14M | 539.00K |
| ChangeInOtherCurrentLiabilities | -1.12M | -984.00K | -917.00K | -1.33M |
| ChangeInOtherCurrentAssets | 322.00K | -328.00K | -2.30M | 222.00K |
| ChangeInPayablesAndAccruedExpense | -52.00K | 4.06M | 343.00K | 1.38M |
| ChangeInAccruedExpense | 821.00K | 2.68M | -505.00K | 748.00K |
| ChangeInPayable | -873.00K | 1.38M | 848.00K | 631.00K |
| ChangeInAccountPayable | -873.00K | 1.38M | 848.00K | 631.00K |
| ChangeInPrepaidAssets | -2.09M | 1.26M | -1.26M | 265.00K |
| OtherNonCashItems | 1.08M | 1.01M | 1.01M | 1.37M |
| StockBasedCompensation | 3.83M | 4.12M | 6.09M | 6.69M |
| AssetImpairmentCharge | 0.00 | 29.52M | 0.00 | |
| AmortizationOfSecurities | -1.25M | -685.00K | -444.00K | 1.14M |
| DepreciationAmortizationDepletion | 362.00K | 332.00K | 341.00K | 248.00K |
| DepreciationAndAmortization | 362.00K | 332.00K | 341.00K | 248.00K |
| Depreciation | 362.00K | 332.00K | 341.00K | 248.00K |
| OperatingGainsLosses | -9.00K | |||
| GainLossOnInvestmentSecurities | -9.00K | |||
| NetIncomeFromContinuingOperations | -57.44M | -44.60M | -40.42M | -65.95M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TARA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|